PL447789A1 - Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of molybdenum in whole blood - Google Patents

Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of molybdenum in whole blood

Info

Publication number
PL447789A1
PL447789A1 PL447789A PL44778924A PL447789A1 PL 447789 A1 PL447789 A1 PL 447789A1 PL 447789 A PL447789 A PL 447789A PL 44778924 A PL44778924 A PL 44778924A PL 447789 A1 PL447789 A1 PL 447789A1
Authority
PL
Poland
Prior art keywords
concentration
whole blood
cancer
risk
molybdenum
Prior art date
Application number
PL447789A
Other languages
Polish (pl)
Inventor
Milena Matuszczak
Adam Kiljańczyk
Wojciech MARCINIAK
Róża Derkacz
Klaudia Stempa
Piotr Baszuk
Marta Bryśkiewicz
Sandra Pietrzak
Cezary Cybulski
Tadeusz Dębniak
Jacek Gronwald
Tomasz Huzarski
Marcin Lener
Anna Jakubowska
Marek Szwiec
Małgorzata Stawicka-Niełacna
Dariusz Godlewski
Artur Prusaczyk
Andrzej Jasiewicz
Tomasz Kluz
Joanna Tomiczek-Szwiec
Ewa Kilar-Kobierzycka
Monika Siołek
Rafał Wiśniowski
Renata Posmyk
Joanna Tretyn-Jarkiewicz
Rodney Scott
Steven Alexander Narod
Jan LUBIŃSKI
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL447789A priority Critical patent/PL447789A1/en
Publication of PL447789A1 publication Critical patent/PL447789A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określenia ryzyka zachorowania na raka u kobiet, będących nosicielkami mutacji w genie BRCA1, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia molibdenu w próbce krwi pełnej osoby badanej, przy czym stężenie < 0,54 µg/l wskazuje na 1,7-krotnie zmniejszone ryzyko zachorowania na raka o różnej lokalizacji, w stosunku do podgrupy kobiet ze stężeniem molibdenu > 0,7 µg/l w próbce krwi pełnej.The subject of the application is a method for determining the risk of cancer in women who are carriers of a mutation in the BRCA1 gene, characterized in that it includes a quantitative assessment of the molybdenum concentration in a whole blood sample of the tested person, wherein a concentration of < 0.54 µg/l indicates a 1.7-fold reduced risk of developing cancer of various locations, compared to the subgroup of women with a molybdenum concentration of > 0.7 µg/l in a whole blood sample.

PL447789A 2024-02-16 2024-02-16 Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of molybdenum in whole blood PL447789A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL447789A PL447789A1 (en) 2024-02-16 2024-02-16 Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of molybdenum in whole blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL447789A PL447789A1 (en) 2024-02-16 2024-02-16 Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of molybdenum in whole blood

Publications (1)

Publication Number Publication Date
PL447789A1 true PL447789A1 (en) 2025-08-18

Family

ID=96736205

Family Applications (1)

Application Number Title Priority Date Filing Date
PL447789A PL447789A1 (en) 2024-02-16 2024-02-16 Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of molybdenum in whole blood

Country Status (1)

Country Link
PL (1) PL447789A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL425603A1 (en) * 2018-05-17 2019-01-02 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women, who are the carriers of mutation in gene BRCA1 and BRCA2 in relation to concentration of arsenic, cadmium, zinc and/or selenium in the blood
PL422787A1 (en) * 2017-09-08 2019-03-11 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women with BRCA1 mutation, depending on their age, hormonal state and concentration of arsenic, cadmium, lead, mercury, iron, zinc, copper and selenium in the blood and/or in the blood serum
WO2019065854A1 (en) * 2017-09-27 2019-04-04 株式会社レナテック Cancer risk evaluation method and cancer risk evaluation system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL422787A1 (en) * 2017-09-08 2019-03-11 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women with BRCA1 mutation, depending on their age, hormonal state and concentration of arsenic, cadmium, lead, mercury, iron, zinc, copper and selenium in the blood and/or in the blood serum
WO2019065854A1 (en) * 2017-09-27 2019-04-04 株式会社レナテック Cancer risk evaluation method and cancer risk evaluation system
PL425603A1 (en) * 2018-05-17 2019-01-02 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women, who are the carriers of mutation in gene BRCA1 and BRCA2 in relation to concentration of arsenic, cadmium, zinc and/or selenium in the blood

Similar Documents

Publication Publication Date Title
Ding et al. Longitudinal trends in perfluoroalkyl and polyfluoroalkyl substances among multiethnic midlife women from 1999 to 2011: The Study of Women′ s Health Across the Nation
Katz-Wise et al. The current state of sexual fluidity research
Gaspari et al. Polycyclic aromatic hydrocarbon-DNA adducts in human sperm as a marker of DNA damage and infertility
Cobo-Cuenca et al. Determinants of satisfaction with life and self-esteem in women with breast cancer
Schietzel et al. Prevalence of healthy aging among community dwelling adults age 70 and older from five European countries
Míguez et al. Continued tobacco consumption during pregnancy and women’s depression and anxiety symptoms
Rahban et al. Association between self-reported mobile phone use and the semen quality of young men
Ignatov et al. Systematic lymphadenectomy in early stage endometrial cancer
Rippberger et al. The association of sarcopenia, telomere length, and mortality: data from the NHANES 1999–2002
Akintoye et al. Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification
Colombe et al. HIV-seroconversion among HIV-1 serodiscordant married couples in Tanzania: a cohort study
PL447789A1 (en) Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of molybdenum in whole blood
Péntek et al. Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists
Creff et al. Returning to work by thyroid cancer survivors 5 years after diagnosis: the VICAN survey
Kirk et al. Interactions Between HR‐pQCT Bone Density and D3Cr Muscle Mass (or HR‐pQCT Bone Structure and HR‐pQCT Muscle Density) in Predicting Fractures: The Osteoporotic Fractures in Men Study
Comerford et al. The burden of metastatic breast cancer on caregiver productivity and quality of life: A survey study in the United States, United Kingdom, and Germany
PL447813A1 (en) Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of zinc in whole blood
PL447790A1 (en) Method for determining the risk of cancer in women carrying a BRCA1 gene mutation depending on the iodine concentration in whole blood
Beardsworth et al. Association of willingness to use hormonal contraception with knowledge: A national survey
Peris et al. Concordance between direct and indirect measurements of free 25-OH vitamin D
PL448873A1 (en) Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the ratio of zinc to copper concentrations in whole blood
PL446899A1 (en) Method of determining the risk of cancer and death in women carrying BRCA1 mutations depending on blood lead concentration
PL433150A1 (en) Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level
Soejima et al. Impact of flexible work arrangements on job resignation after cancer diagnosis among Japanese young adult cancer survivors
Drageset et al. Monitoring of disseminated tumor cells in bone marrow in high‐risk breast cancer patients treated with high‐dose chemotherapy